Tuesday, May 24, 2022
HomeBusinessGlaxo boosted by strong demand for its shingles vaccine

Glaxo boosted by strong demand for its shingles vaccine


Glaxo boosted by strong demand for its shingles vaccine ahead of planned demerger of its consumer health arm

A rebound in demand for its shingles vaccine has boosted Glaxosmithkline ahead of the planned demerger of its consumer health business.

The pharma giant reported a 32 per cent rise in first quarter revenues to £9.8billion while profits jumped 39 per cent to £2.6billion.

Sales of the Shingrix shingles vaccine doubled to nearly £700million following disruption a year ago when Covid jabs were given priority. 

Shingles relief: Glaxosmithkline reported a 32% rise in first quarter revenues to £9.8bn while profits jumped 39% to £2.6bn

Shingles relief: Glaxosmithkline reported a 32% rise in first quarter revenues to £9.8bn while profits jumped 39% to £2.6bn

GSK also raked in £1.3billion of sales of its coronavirus antibody treatment Xevudy.

Chief executive Emma Walmsley said she expects sales over the full year to rise by between 5 per cent and 7 per cent. 

The results came ahead of the planned demerger of its consumer health business, which owns Sensodyne toothpaste and Panadol painkillers and will become a separate company called Haleon in July.

Astrazeneca’s Enhertu drug, intended for patients suffering from breast cancer to slow progression of the disease and increase survival rates, has been designated a breakthrough treatment by US regulators.

Advertisement

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments